Bicara Therapeutics Inc. (BCAX) Stock Price & Analysis

Bicara Therapeutics Inc. (BCAX) fell 2.56% to USD 27.02 as of July 25, 2026 at 03:50 UTC, according to Nexqual real-time market data.

BCAX last closed at USD 27.73; the session ranged USD 26.69–28.22 on volume of 466,470 shares. Market capitalization is $1.78B, with a 52-week range of USD 9.57–30.99 (NGM). Source: Nexqual, July 25, 2026 at 03:50 UTC.

Key Statistics (as of July 25, 2026 at 03:50 UTC)

Technical Analysis (BCAX)

Nexqual's technical model rates BCAX "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 03:50 UTC.

Analyst Ratings (BCAX)

Wall Street analysts rate BCAX "None" based on 13 analysts, with a mean price target of USD 31.46 (range USD 16–46), per Nexqual as of July 25, 2026 at 03:50 UTC.

Earnings (BCAX)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 03:50 UTC.

Financials & Fundamentals (BCAX)

Source: Nexqual, July 25, 2026 at 03:50 UTC.

Financial Health Score (BCAX)

Nexqual rates Bicara Therapeutics Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:50 UTC.

Ownership (BCAX)

Source: Nexqual, July 25, 2026 at 03:50 UTC.

Leadership (BCAX)

Bicara Therapeutics Inc. is led by Claire Mazumdar Clemon (age 35), CEO & Director, per Nexqual as of July 25, 2026 at 03:50 UTC.

Major Backers & Investors (BCAX)

Notable institutional backers of Bicara Therapeutics Inc. include T. Rowe Price, RA Capital Management, L.P., Siren, L.L.C., according to Nexqual as of July 25, 2026 at 03:50 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 03:50 UTC.

From Bicara Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• Any patents that issue based on these patent applications, if granted and all appropriate maintenance fees paid, are expected to expire in 2033, not including any patent term adjustment, patent term extension, SPC, or the like. 21 Table of Contents As of March 24, 2026, we also solely own a patent portfolio containing five patent families each containing pending patent applications that, if issued, may provide additional intellectual property protection for ficerafusp alfa.
• In the U.S., the FDA regulates biological products under the Federal Food, Drug, and Cosmetic Act, or the FDCA, the Public Health Service Act, or the PHSA, and their implementing regulations.
• Intellectual Property We seek to protect the intellectual property and proprietary technology that we consider important to our business, including by pursuing patent applications that cover our product candidates and methods of using the same, as well as any other relevant inventions and improvements that we believe to be commercially important to the development of our business.
• We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.

Partnerships

• Contract Transfer and License Agreement with Biocon On October 1, 2019, we entered into a Contract Transfer and License Agreement, or the Biocon Agreement, with Biocon Limited, or Biocon.
• Clinical Trial Collaboration and Supply Agreement with MSD On May 19, 2022, we entered into a Clinical Trial Collaboration and Supply Agreement, or the MSD Agreement, with MSD International GmbH, or MSDIG, and MSD International Business GmbH, MSDIB, and collectively with MSDIG, MSD.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:50 UTC. This page is informational and not investment advice.